Please click here for the Trust's medicines formulary.
NICE Medicines Guidance
The National Institute for Health and Clinical Excellence (NICE(external link)) advises the National Health Service (NHS) regarding treatments that should be made available. NICE issues this advice in several forms.
The most well known of these are public health guidance(external link) that aims to prevent ill health, clinical guidelines(external link) which cover the treatment of individual conditions, and technology appraisals(external link) that describe the place in treatment of individual medicines or medical procedures.
Camden & Islington NHS Foundation Trust has a responsibility to ensure that treatments recommended by NICE are made available to patients. The trust must also ensure any treatments that NICE recommend should not be used, are not used.
Under the NHS Constitution(external link), patients have the right to receive medicines and treatments that are recommended in NICE technology appraisals if their doctor thinks that these treatments are right for them. When NICE recommends a treatment, the trust must make it available within 3 months of that recommendation.
In a letter from the NHS chief executive Innovation, Health and Wealth, publication of NHS formularies(external link) PDF (new window) (2012), the Department of Health has stated that all NHS Organisations should publish information which sets out which NICE technology appraisals are included in their local formularies by April 1st 2013.
In Camden & Islington NHS Foundation Trust, the Drug and Therapeutics Group discusses new NICE medicines related technology appraisals and decides if they are relevant to the services that the trust provides. This group has agreed that the following technology appraisals related to the use of medicines are relevant to the services we are responsible for providing:
TA77(external link) PDF (new window) Zaleplon, zolpidem and zopiclone for the short-term management of insomnia
TA98(external link) PDF (new window) Methylphenidate, atomoxetine, and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
TA114 (external Link) PDF (new window) Drug misuse - methadone and buprenorphine
TA115 (external Link) PDF (new window) Drug misuse - naltrexone
TA123 (external Link) PDF (new window) Varenicline for smoking cessation
TA213(external link) PDF (new window) Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years
TA217(external link) PDF (new window) Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimers disease
The Drug and Therapeutics Group has made sure that the recommendations in these technology appraisals have been included in the trust's formulary and prescribing guidelines. All recommended medicines have been made available for doctors to prescribe.
The North Central London Joint Formulary Committee and the trust's Drug and Therapeutics Group are also responsible for deciding whether medicines that have not been assessed by NICE should be made available.